Deutsche Bank AG Takes $2.04 Million Position in Sarepta Therapeutics, Inc. $SRPT

Deutsche Bank AG purchased a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 113,724 shares of the biotechnology company’s stock, valued at approximately $2,044,000.

Several other institutional investors have also recently bought and sold shares of SRPT. Vanguard Group Inc. raised its position in shares of Sarepta Therapeutics by 9.2% during the fourth quarter. Vanguard Group Inc. now owns 11,810,729 shares of the biotechnology company’s stock worth $254,167,000 after acquiring an additional 993,283 shares during the last quarter. AQR Capital Management LLC boosted its holdings in Sarepta Therapeutics by 454.6% in the fourth quarter. AQR Capital Management LLC now owns 7,796,535 shares of the biotechnology company’s stock valued at $167,781,000 after acquiring an additional 6,390,860 shares during the last quarter. First Trust Advisors LP increased its position in Sarepta Therapeutics by 107.6% in the first quarter. First Trust Advisors LP now owns 4,135,788 shares of the biotechnology company’s stock worth $89,995,000 after purchasing an additional 2,143,211 shares during the period. Erste Asset Management GmbH increased its position in Sarepta Therapeutics by 1.6% in the fourth quarter. Erste Asset Management GmbH now owns 2,728,945 shares of the biotechnology company’s stock worth $58,727,000 after purchasing an additional 43,000 shares during the period. Finally, Bank of America Corp DE raised its holdings in Sarepta Therapeutics by 26.6% during the 1st quarter. Bank of America Corp DE now owns 2,145,926 shares of the biotechnology company’s stock worth $46,695,000 after purchasing an additional 450,336 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on SRPT. Zacks Research raised shares of Sarepta Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Piper Sandler dropped their price target on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating for the company in a research note on Thursday, July 9th. Weiss Ratings lowered shares of Sarepta Therapeutics from a “sell (d)” rating to a “sell (e+)” rating in a report on Wednesday, August 19th. Wall Street Zen cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Sarepta Therapeutics in a report on Tuesday, July 28th. Nine analysts have rated the stock with a Buy rating, six have issued a Hold rating and five have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $25.06.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock opened at $20.86 on Friday. The company has a current ratio of 4.42, a quick ratio of 2.62 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $2.20 billion, a P/E ratio of -7.19, a PEG ratio of 0.32 and a beta of 0.23. The business has a 50-day moving average of $17.73 and a 200-day moving average of $18.32. Sarepta Therapeutics, Inc. has a 1 year low of $14.68 and a 1 year high of $25.32.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $0.42. Sarepta Therapeutics had a negative net margin of 13.48% and a negative return on equity of 1.60%. The business had revenue of $401.25 million for the quarter, compared to the consensus estimate of $366.39 million. During the same period last year, the company posted $2.02 EPS. Sarepta Therapeutics’s revenue for the quarter was down 34.3% on a year-over-year basis. On average, equities analysts anticipate that Sarepta Therapeutics, Inc. will post 3.43 EPS for the current year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.